11/05/2024 | Press release | Distributed by Public on 11/05/2024 15:48
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $37.7 | (1) | 05/01/2025 | Common Stock | 13,392 | 13,392 | D | ||||||||
Stock Option (Right to Buy) | $44.33 | (1) | 08/08/2025 | Common Stock | 84,308 | 84,308 | D | ||||||||
Stock Option (Right to Buy) | $47.6 | (1) | 08/07/2026 | Common Stock | 109,536 | 109,536 | D | ||||||||
Stock Option (Right to Buy) | $66.97 | (1) | 08/05/2027 | Common Stock | 115,724 | 115,724 | D | ||||||||
Stock Option (Right to Buy) | $120.46 | (2) | 08/06/2028 | Common Stock | 25,944 | 25,944 | D | ||||||||
Performance Restricted Stock Units | (3) | (4) | (4) | Common Stock | 6,984 | 6,984 | D | ||||||||
Performance Stock Options (Right to Buy) | $94.52 | (4) | 08/15/2029 | Common Stock | 21,704 | 21,704 | D | ||||||||
Stock Options (Right to Buy) | $94.52 | (5) | 08/15/2029 | Common Stock | 28,940 | 28,940 | D | ||||||||
Performance Restricted Stock Units | (3) | (6) | (6) | Common Stock | 8,873 | 8,873 | D | ||||||||
Performance Stock Options (Right to Buy) | $84.61 | (6) | 08/15/2030 | Common Stock | 23,881 | 23,881 | D | ||||||||
Stock Options (Right to Buy) | $84.61 | (7) | 08/15/2030 | Common Stock | 29,391 | 29,391 | D | ||||||||
Stock Options (Right to Buy) | $52.83 | (8) | 11/01/2030 | Common Stock | 38,252 | 38,252 | D | ||||||||
Performance Restricted Stock Units | (3) | (6) | (6) | Common Stock | 9,423 | 9,423 | D | ||||||||
Performance Stock Options (Right to Buy) | $68.54 | (6) | 02/01/2031 | Common Stock | 25,945 | 25,945 | D | ||||||||
Stock Options (Right to Buy) | $68.54 | (9) | 02/01/2031 | Common Stock | 51,890 | 51,890 | D | ||||||||
Performance Restricted Stock Units | (3) | (10) | (10) | Common Stock | 51,261 | 51,261 | D | ||||||||
Restricted Stock Units | (3) | (11) | (11) | Common Stock | 25,630 | 25,630 | D | ||||||||
Stock Options (Right to Buy) | $74.91 | (12) | 08/15/2034 | Common Stock | 69,061 | 69,061 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Kelderman Kim 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413 |
X | Chief Executive Officer |
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed. | 11/05/2024 |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Fully exercisable. |
(2) | Options to purchase 6,484 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 6,488 shares vest on each of 8/6/2024 and 8/6/2025. |
(3) | Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. |
(4) | Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(5) | Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025. |
(6) | Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(7) | Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. |
(8) | Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. |
(9) | Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. |
(10) | Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(11) | 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. |
(12) | Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. |